NFKB1 and type 1 diabetes mellitus: Several animal and cell studies that explored AAT treatment reported AAT treatment reduces inflammation and retinal neurodegeneration via downregulation of NF-κB, iNOS, and TNF-α in the T1DM/Streptozotocin (STZ) mouse model of T1DM [83].